Article
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
PharmacoEconomics - 1 Nov 2012
Panattoni Laura, Brown Paul M, Te Ao Braden, Webster Mark, Gladding Patrick
Abstract excerpt
BACKGROUND: A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel. The frequency of the *2 allele varies by ethnicity and the Maoris, Asians and Pacific Islanders of New Zealand have a relatively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.